CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
克服肿瘤 CAR-T 细胞治疗障碍的表观遗传学见解与创新
英文原题：Epigenetic insights and innovations for overcoming barriers in CAR-T cell therapy for cancer.
查看英文原题
Epigenetic insights and innovations for overcoming barriers in CAR-T cell therapy for cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
在过去的几十年里，嵌合抗原受体（CAR）-T 细胞疗法彻底改变了肿瘤免疫治疗，尤其是对血液系统肿瘤。然而，其针对实体瘤的疗效往往受到诸多障碍的制约。现代表观基因组分析技术的进步加深了我们对表观遗传调控如何塑造 CAR-T 细胞行为的理解。表观遗传机制作为一种无形的力量，通过调控参与代谢、分化、表型、迁移、持久性和整体功能的关键基因来决定 CAR-T 细胞的命运。近期在表观遗传监测与操控方面的创新，为解决限制 CAR-T 细胞性能的挑战提供了新策略。在本综述中，我们审视 CAR-T 细胞的表观遗传图景，并讨论基于表观遗传的潜在策略，以增强 CAR-T 细胞功能并克服 CAR-T 细胞疗法的局限性。试验注册号：不适用。
展开英文摘要原文
Over the past several decades, chimeric antigen receptor (CAR)-T cell therapy has revolutionized cancer immunotherapy, particularly for hematological cancers.
However, its effectiveness against solid tumors is often hindered by numerous barriers. Advances in modern epigenomic profiling technologies have deepened our understanding of how epigenetic regulation shapes CAR-T cell behavior. Epigenetic mechanisms act as an unseen force that governs CAR-T cell fate by modulating key genes involved in metabolism, differentiation, phenotype, migration, persistence, and overall function.
Recent innovations in epigenetic monitoring and manipulation have provided new strategies to address the challenges that restrict CAR-T cell performance. In this review, we examine the epigenetic landscape of CAR-T cells and discuss potential epigenetic-based strategies to enhance CAR-T cell function and overcome limitations in CAR-T cell therapy. Trial registration number: not applicable.
论文信息
- 作者
- Poluektova VB、Zuevskaya SN、Suvon Y、Gulnihol S、Turakulov R、Umirkulova F
- 第一作者单位
- Department of Infectious Diseases, Institute of Public Health named after F.F. Erisman, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.Russia
- 通讯作者单位
- Department of Infectious Diseases, Institute of Public Health named after F.F. Erisman, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia. zuevskaya_s_n@outlook.com.Russia
- 文献类型
- 综述
- 期刊
- Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026 Sep
- 原文标识
- PubMed 41874947 · DOI 10.1007/s12094-026-04310-y